Madison Area Lyme Support Group

Pharmaceutical giant Gilead recalled one batch of its COVID-19 antiviral drug Veklury, the brand name for remdesivir, after glass particles were discovered in vials of the drug, Newsweek reported.

A company investigation, prompted by a customer complaint, confirmed the presence of glass, according to the company recall notice posted on the U.S. Food and Drug Administration (FDA) website.

Gilead distributed the batch, identified as Veklury lot No. 47035CFA across the U.S. beginning on July 16. The batch isn’t set to expire until November 2025.

If a product containing glass is injected, it may result in localized swelling or, “the glass particulate can potentially travel, through the blood vessels, to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death,” the company warned in the recall notice.

Gilead said it is informing distributors and customers via a letter sent to UPS Next Day Air. The letter advises facilities that have the recalled drug to stop using it and return the vials to the company following the instructions in the letter.

Gilead said it has not received any reports of adverse events related to this lot.

The company didn’t say where the lots were manufactured or by whom and did not respond to The Defender’s request for comment on those questions.  (See link for article)

________________

**Comment**

Similarly to the fact COVID tests and gene therapy injections should ALL be recalled and destroyed with a public apology, Remdesivir has been nothing but a major problem since it was rolled out as part of the ‘Fauci Death Protocol.’ 

For more:

• https://madisonarealymesupportgroup.com/2023/01/11/wrongful-death-agent-remdesivir/
• https://madisonarealymesupportgroup.com/2024/09/19/remdesivir-what-you-should-know/
• https://madisonarealymesupportgroup.com/2020/10/03/gilead-announces-its-selling-remdesivir-direct-lining-the-pockets-of-many-government-officials/
• https://madisonarealymesupportgroup.com/2020/10/01/gilead-big-pharma-and-the-who-an-unholy-trifecta-of-corruption-and-bioterrorism/
• https://madisonarealymesupportgroup.com/2020/10/26/remdesivir-gets-fda-approval-but-who-says-drug-ineffective-for-covid/
• https://www.thegatewaypundit.com/2020/06/stunning-faucis-remdesivir-costs-9-per-dose-will-sold-3000-per-dose-china-company-linked-soros-will-also-mass-produce-drug/  Excerpt:

Going back to 1997, Donald Rumsfeld chaired the Board of Directors at Gilead and after 2001 he held share packages valued at $5-25 Million. Gilead originally developed Tamiflu. George P Shultz, US Secretary of State also was on the board. He sold stocks at a value of more than $7 million. CA governor’s Pete Wilson’s wife also sat on the board.

“‘I don’t know of any biotech company that’s’ so politically well-connected [as Gilead],‘ Andrew McDonald, of the analyst firm Think Equity Partners, told Fortune.” (Source: “Virus Mania, How the Medical Industry Continually Invents Epidemics Making Billion Dollar Profits At Our Expense”)

• https://principia-scientific.org/a-tale-of-2-drugs-deep-state-chose-money-power-over-lives/  Excerpt:

  Approximately $70 million in U.S. taxpayer funding began Gilead’s partnership with the U.S. Army, Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) to develop remdesivir. Initially for treating Ebola, it failed to show benefit and was shelved. If remdesivir is used to treat COVID-19, Gilead shareholders, not the taxpayers, will profit.